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abstRact
IntroductIon: High-dose recombinant human erythro-
poietin (rhEpo) has been shown to improve cognitive per-
formance in both healthy volunteers and in patients suffer-
ing from diseases affecting the brain. The aim of this study 
was to examine whether administration of low-dose and 
even micro-dose rhEpo improves cognitive performance in 
healthy volunteers. 
Methods: We enrolled 25 healthy volunteers in a double-
blind, randomised, placebo-controlled study to receive ei-
ther low-dose rhEpo (n = 8, 60 IU/kg/week), micro-dose 
rhEpo (n = 9, 20 IU/kg/week), or saline (n = 8) for 4 weeks. 
Two cognitive performance-tests, the Raven Standard Pro-
gressive Matrices (Raven) and the Number Finder (NUFI), 
were performed during the first and last day of the study 
period. Semi-structured interviews were conducted weekly 
and were coded according to a scale. 
results: Subjects receiving micro-dose rhEpo improved 
significantly measured by the Raven score (p = 0.04), and 
subjects receiving low-dose rhEpo treatment improved sig-
nificantly measured by the NUFI score (p = 0.047), whereas 
no improvement was found in experienced cognitive per-
formance in any of the groups. We found no significant dif-
ference in either Raven, NUFI or self-reported results be-
tween the groups.
conclusIons: In this small study, we found no significant 
effect of low-dose or micro-dose rhEpo on visual attention, 
cognitive performance in complex cognitive tasks or self-ex-
perienced cognitive performance compared with placebo. 
FundIng: The Aase and Ejnar Danielsen’s Foundation. Dan-
ish Ministry of Science, Innovation and Higher Education. 
trIal regIstratIon: ClinicalTrials.gov identifier: 
NCT03093506
Recombinant human erythropoietin (rhEpo) has a well-
known stimulating effect on the erythropoiesis [1], but it 
also has effects on neuroprotection, brain development 
and cognitive performance [2, 3].
In studies in mice, Epo and Epo receptors have been 
found to be expressed in the brain [4], and when these 
receptors are activated, cognitive performance improves 
[5]. It has been shown that rhEpo improves the cognitive 
performance in healthy human volunteers [2]. 
Furthermore, it has been shown that high-dose rhEPO 
has a positive effect on cognitive dysfunction in patients 
suffering from depression and bipolar disorder with ef-
fects on sustained attention, speed of complex informa-
tion processing and working memory accuracy [6-8]. In 
patients with schizophrenia, long-term high-dose rhEpo 
administration also seems to improve cognitive perfor-
mance [9, 10], whereas no improvement has been found 
in patients suffering from multiple sclerosis [11, 12]. 
RhEpo crosses an intact blood-brain barrier in a 
dose-dependent manner [13]. Most studies investigating 
the relationship between rhEpo treatment and cognitive 
performance have used high doses of rhEpo (30,000-
40,000 IU). It is not clear whether rhEpo in lower doses 
also improves the cognitive performance. One study us-
ing low-dose rhEpo (5,000 IU/week) failed to show any 
cognitive effect [14]. In a recent study from our unit, 
low-dose rhEpo (5,000 IU/week) was administered to 
healthy subjects who in general experienced an im-
proved cognitive performance [15]. The possible  
changes in cognitive performance were, however, not 
measured directly.
We hypothesised that 4-week administration of 
low-dose rhEpo (60 IU/kg/week) and even micro-dose 
rhEpo (20 IU/kg/week) improves the cognitive perfor-
mance of complex cognitive tasks, tasks involving visual 
attention and self-experienced cognitive performance in 
healthy volunteers.
mEthOds
subjects
A total of 25 men volunteered to participate. The inclu-
sion criteria were: healthy males between 18-45 years of 
age, a normal medical examination and weekly exercise 
for 0-5 hours. The exclusion criteria were: daily smoking, 
previous use of performance-enhancing drugs, elite ath-
letes and presence of cardiovascular or metabolic dis-
ease. All subjects agreed to maintain their level of physi-
cal activity unchanged throughout the trial period. The 
primary endpoint was improvement in mitochondrial 
function, whereas the cognitive improvement presented 
in this article was a secondary endpoint.
Subjects were informed about the possible risks and 
discomfort involved before giving their written consent 
to participate. The study was conducted according to 
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the Declaration of Helsinki and was approved by the 
Ethical Committee of Copenhagen (H-1-2011-098 and 
H-1-2011-099).
Experimental design
The subjects were randomly allocated for either low-
dose rhEpo (NeoRecormon Roche, Schweiz, 60 IU/kg/
week, n = 8, “Low-dose Group”), micro-dose rhEpo (20 
IU/kg/week, n = 9, “Micro-dose Group”) or saline (n = 8, 
“Control Group”) in a double-blind between-groups de-
sign. A few days prior to treatment start, the subjects 
performed incremental cycling to determine their maxi-
mal oxygen (VO2max) uptake. The groups were ran-
domised in strata according to their VO2max. Prior to 
rhEpo/saline administration on the first day and after 
the 4 weeks of treatment, the subjects underwent two 
cognitive performance tests; the Raven Standard Pro-
gressive Matrices (Raven), and the Number Finder 
(NUFI). The cognitive performance tests were adminis-
tered using a computerised version coined APRO30 
(Ability Profile) developed by Marine Profile (Halmstad, 
Sweden). Weekly semi-structured interviews were con-
ducted by a blinded interviewer. All interviews and per-
formance tests were carried out in the same room and 
under highly similar conditions. An observer was present 
in the room during the computer tests, and interference 
from the sorrounding environment was avoided. 
Epo treatment
The first doses of rhEpo/saline were administered sub-
cutaneously on three consecutive days in order to 
achieve a steady-state serum concentration. Hereafter, 
the weekly dose was divided into two injections per 
week for 4 weeks. The rhEpo was dissolved into 0.7 ml 
of saline. Once a week, a venous blood sample was 
drawn to assess blood haematocrit (Radiometer, ABL 80, 
Denmark). If the haematocrit reached ≥ 50%, the rhEpo 
dose was reduced to maintain the haematocrit at ~ 50% 
in order to minimise the risk of thrombosis. The subjects 
were instructed to take daily iron supplements of 100 
mg, starting two weeks prior to the rhEpo treatment and 
continuing throughout the study period. 
Cognitive evaluation
The Raven test
The Raven test is a non-verbal test based on figural sti-
muli. It contains complicated pattern solving and meas-
ures the reasoning and problem solving ability and the 
ability for visual analysis. The Raven test consists of 60 
items, each containing a 3 × 3 matrix, in which one field 
is blank. The subject is asked to find the missing pattern 
from eight suggestions. The level of complexity increases 
throughout the test process.
All subjects were instructed in the same way and 
with the same words that they would be evaluated on 
both speed and accuracy. A programme calculated a 
score from 1 to 9 (best) for both speed and accuracy. 
Evaluation of this test was based on the sum of the two 
scores (ordinal scale, 2-18).
The Number Finder test
The Number Finder (NUFI) test measures the ability to 
seek information visually as well as the ability to per-
ceive and organise visual information. In a matrix of 64 
fields, each field is numbered randomly from 1 to 64. 
Each field is also identified with a corresponding num-
ber. When a number is shown on a screen, the subject 
must visually locate it in the matrix and enter the corre-
sponding number. The subject has five minutes to find 
and enter as many numbers as possible. We evaluated 
this test on a ratio scale by counting the number of cor-
rectly found fields during the five-minute test period.
Interviews
The weekly semi-structured interviews were transcribed 
and any change in experienced cognitive performance 
was rated by three independent and blinded raters as 
suggested by Kvale and Brinkmann [16]. A scale ranging 
from -3 to 3 was used for the rating (-3: High experi-
enced decrease in cognitive performance, 0: No change, 
3: High experienced improved cognitive performance). 
When in doubt, the final score was based on a discus-
sion between the raters. The subjects’ responses were 
coded to identify what parameters the subjects were re-
ferring to when reporting experienced differences in 
their cognitive performance, e.g. ability to concentrate, 
or memory.
In order to assess different aspects of cognitive per-
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formance, we decided to make use of both the Raven 
test, the NUFI test and self-reporting. We chose the 
Raven test because it has high validity and reliability, it is 
very often used for cognitive screenings and focuses on 
complex cognitive thinking. By evaluating speed and ac-
curacy, we focused on the ability to perform a cognitive 
task under self-imposed time pressure given that the in-
struction for the test was to perform as fast and accu-
rate as possible [17]. We chose a visual perception test, 
NUFI, because it measures the ability to perceive and or-
ganise visual information [18]. Finally, we chose self-re-
porting since qualitative information can give more pre-
cise information as to how the subjects experience the 
changes in cognitive performance and what kind of 
changes they experience.
statistical analysis
The data are presented as mean ± standard error of 
mean (SEM) or as median [range]. For the NUFI test, 
one-way ANOVA was used to compare the groups’ 
changes in score, and paired t-test was used to test for 
changes within each group. The scores from the Raven 
test and the interviews were not considered normally 
distributed, and non-parametric tests were therefore 
used. Specifically, the Kruskal-Wallis one-way ANOVA 
was used to compare the groups’ changes in score, and 
the Wilcoxon Signed Ranks test was used to test for 
changes within each group. One-tailed p values were 
used. Statistical analyses were performed using the Sta-
tistical Package for the Social Sciences (SPSS, version 
20.0).
Trial registration: ClinicalTrials.gov identifier: 
NCT03093506.
REsUlts
A total of 25 healthy men (age 27 ± 1.3 years, height 183 
± 1.3 cm, weight 82 ± 2.3 kg, Body Mass Index (BMI) 25 ± 
0.6, VO2max 3,518 ± 90 ml O2/min) participated in this 
study. The three groups compared well. The total rhEpo-
dose administered was ~32,000 IU/subject for the Low-
dose Group and ~14,000 IU/subject for the Micro-dose 
Group. The weekly given dose after the initial three con-
secutive doses was ~5,000 IU/week for the Low-dose 
Group and ~2,200 IU/week for the Micro-dose Group. 
One subject from each rhEpo treatment group re-
ceived less than half the planned amount of rhEpo due 
to a high haematocrit value, and one dose was missed in 
another three subjects receiving low-dose and one re-
ceiving micro-dose rhEpo. 
Blood tests
Before the treatment period started, the haematocrit 
(%) was 43.8 ± 0.8 for the Low-dose Group, 43.7 ± 0.7 
for the Micro-dose Group and 42.9 ± 0.9 for the Control 
Group. The haematocrit increased significantly for the 
Low-dose Group and the Micro-dose Group, whereas 
the haematocrit for the Control Group remained the 
same during the treatment period (Figure 1).
Raven
The scores before the initiation of rhEpo-treatment 
were not significantly different between the groups. 
After the treatment period, a significant improvement 
was only found for the Micro-dose Group (p = 0.04) 
(table 1). However, the improvements observed in the 
three groups were not significantly different (p = 0.36).
number Finder
The scores before the treatment period were not signifi-
cantly different between the groups. After the treat-
ment period, a significant improvement was found only 
for the Low-dose Group (p = 0.047) (table 2). There was 
no significant difference in the improvements between 
the groups (p = 0.07).
Interviews
Nine subjects experienced improved cognitive perfor-
mance and four subjects experienced decreased cogni-
tive performance during the treatment period. In the 
Low-dose Group, 50% of the volunteers (four subjects) 
experienced improved cognitive performance, whereas 
this was the case in only 33% (three subjects) in the Mi-
tablE 1
Raven Standard Progressive Matrices-scores. 
score
group n
pre-treatment, 
mean ± sEm
post-treatment, 
mean ± sEm
difference,  
median (range) p-valuea
Low-dose 8 14.3 ± 0.6 15.0 ± 0.8 0.5 (–1-3) 0.07
Micro-dose 9 13.4 ± 0.5 14.1 ± 0.6 0 (0-2) 0.04
Control 8 14.0 ± 0.2 14.3 ± 0.3 0 (–1-1) 0.18
SEM = standard error of the mean 
a) Within-group differences (1-tailed).
tablE 2
Number Finder-scores: correctly found fields.  
score, mean ± sEm
group n pre-treatment post-treatment difference p-valuea
Low-dose 8 43.0 ± 3.6 47.1 ± 4.6  4.1 ± 2.1 0.047
Micro-dose 9 43.0 ± 2.6 41.6 ± 2.8 –1.4 ± 2.0 0.25
Control 8 40.6 ± 2.3 42.4 ± 3.0  1.8 ± 1.5 0.14
SEM = standard error of the mean 
a) Within-group differences (1-tailed).
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cro-dose Group and 25% (two subjects) in the Control 
Group (table 3). Two of the subjects participating in this 
study were given the highest possible score, 3 (high im-
provement in experienced cognitive performance), and 
they were in the Low-dose and the Micro-dose Group, 
respectively. However, none of the groups improved sig-
nificantly in self-experienced cognitive performance 
(Low-dose Group p = 0.07, Micro-dose Group p = 0.10, 
Control Group p = 0.50), and there was no significant dif-
ference in the improvements between the groups (p = 
0.26).
The results from the interviews suggested that 
those subjects who experienced an improved cognitive 
performance experienced the following: improved  
energy level, improved attention in focusing when per-
forming complex reading tasks, improved ability to cate-
gorise and organise thoughts, better structure in 
thoughts, facilitation in decision-making processes and 
improved ability to maintain task focus. The subjects ex-
periencing decreased cognitive performance experi-
enced decreased energy level, decreased ability to main-
tain task focus and decreased memory.
discUssiOn
Compared with placebo, we found no improvement of 
cognitive performance in complex cognitive tasks (Raven 
test), visual attention (NUFI test) or self-experienced 
cognitive performance in the two rhEpo-treated groups 
despite increased haematocrit levels in both. However, 
there was a within-group improvement in Raven score in 
the Low-dose Group and a within-group improvement in 
NUFI score in the Micro-dose Group. Some volunteers in 
each group experienced improved energy level, atten-
tion in focusing and ability to maintain task focus. How-
ever, this was not significantly different between the 
groups. 
Previous studies have shown that in cases of anae-
mia, rhEpo improved cognitive performance by correct-
ing the haematocrit [19]. In people without anaemia, 
high-dose administration of rhEpo (40,000 IU) has been 
shown to increase hippocampal activation during visual 
memory tasks [20] and to improve verbal fluency in hu-
man volunteers, also in the absence of haematological 
changes [2]. The impact of rhEpo on cognition may be 
due to expression of Epo receptors in the brain, even 
though it is known that Epo receptors are less expressed 
in healthy brains than in injured brains [2, 20]. There are 
several serious side-effects of rhEpo therapy [8, 10], and 
it is therefore important to consider the lowest effective 
dose. Only few human studies have examined the cogni-
tive effects of low doses of rhEpo. So far, low-dose rhE-
po treatment has, however, not been found to improve 
cognitive performance [11, 14]. Our findings support 
that without anaemia, low-dose rhEpo may not be suffi-
cient to improve cognitive performance in healthy vol-
unteers. 
The primary limitation of the present study is the 
small sample size. This is due to the fact that the cogni-
tive endpoint was not the primary endpoint. 
Accordingly, the conclusions of this study are hypothe-
sis-generating rather than fact-establishing. This study 
was inspired by an earlier study from our unit [15] that 
was based on a small (n = 6), very homogenous group. 
However, the present study was made in a more hetero-
geneous and randomised group of healthy men with 
very different physical fitness levels and very different 
educational and socioeconomic backgrounds, since one 
of the aims of this study was investigation of the exter-
nal validity in relation to the earlier study. However, the 
diversity of the group resulted in large standard devia-
tions that made it less likely to detect small changes in 
cognitive performance. 
cOnclUsiOns
In this small study, we found no significant effect of low-
dose or micro-dose rhEpo treatment on visual attention, 
cognitive performance in complex cognitive tasks or self-
experienced cognitive performance compared with pla-
cebo. To conclude whether low-dose rhEpo treatment 
has any effect on cognitive performance, further studies 
with larger sample sizes are needed.
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